# A potential simple tool to estimate 90-day mortality after total hip arthroplasty: Comparison with established comorbidity measures based on 44,214 patients from the Swedish Hip Arthroplasty Register

Anne Garland 1,2,3,M.D., Szilard Nemes2, 4, Erik Bülow2, 4, Ph.D., Göran Garellick 2,4, M.D., Ph.D., Nils P. Hailer 1,2, M.D.

1 Department of Orthopaedics, Institute of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden

2 Swedish Hip Arthroplasty Register, Gothenburg, Sweden

3 Department of Orthopaedics, Visby Hospital, Visby, Sweden

4 Department of Orthopaedics, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence:anne.l.garland@gmail.com, Tel: +46-498-26 80 00, Orthopeadic Department, Visby Hospital, St Göransgatan 10, 621 84 Visby, Sweden

[nils.hailer@surgsci.uu.se](mailto:nils.hailer@surgsci.uu.se)

szilard.nemes@registercentrum.se

goran.garellick@registercentrum.se

# Abstract

## Background and purpose

Current comorbidity measures such as Charlson Comorbidity Index, Elixhauser Score, and the RxRisk-V Score are inconvenient for clinical use. The more simple ASA classification has not been investigated with respect to its ability to predict mortality after THA. Therefore, our aim of this study was compare the clinically used comorbidity measure ASA with the diagnosed based Charlson Comorbidity Index (CCI) and Elixhauser Score, and the prescription based RxRisk-V in regard to the risk of early postoperative mortality after THA, and try to find a potential simple estimation tool for the clinical setting.

## Patients and methods

We performed a nationwide retrospective cohort study analysing 44,214 patients between 18 and 100 years who hade received a THA due to primary osteoarthritis. The Kaplan-Meier method was used to calculate unadjusted cumulative survival. Logistic regression models were fitted to calculate crude and adjusted odds ratios (OR) with 95% confidence intervals (CI). The performance of the logistic regression models was evaluated by its discrimination capacity using c-statistics. Our primary endpoint was death within 90 day after surgery.

## Results

Unadjusted cumulative 90-day survival was 99.7 (CI 99.68 to 99.78) and the number of deaths 115. As expected we found that increasing age and male gender were associated with an increased risk of 90-day mortality. CCI, Elixhauser Score, and the RxRisk-V Score performedbetter in predicating 90-day and one-year mortality than the included dimensions separately.The RxRisk-V Scoreperformed better than diagnose based comorbidity measures in predicting 90-day mortality with an AUC= 0.66. Best predictive performance was found for the combination model of age, gender, ASA, presence of heart infarction or renal disease for the last 12 months prior to THA surgery (AUC 0.81).

## Interpretation

Our results of this nationwide cohort study indicate that a less data demanding comorbidity measure, i.e. the suggested combination of age, gender, ASA score, presence of heart infarction or renal disease for the last 12 months prior to THA surgery, or even ASA alone, serves us just as well if not better than the commonly used more complex diagnose based or prescription based coding algorithms.

# Introduction

The comorbidity burden among individuals undergoing THA procedures has increased in the past decades.([1](#_ENREF_1), [2](#_ENREF_2)) while the early postoperative mortality after THA is low and has decreased over the last years.([3-6](#_ENREF_3)) The higher prevalence of comorbidity in patients undergoing THA may be multifactorial, i.e. caused by an ageing population, improved pre- and post-operative care, improved treatment of comorbid conditions, or a result of more comorbidities being registered. Several studies have verified the connection between an increased comorbidity burden and a poorer outcome on a population level, i.e. an increased risk of early postoperative mortality, an increased risk of revision([1](#_ENREF_1), [7](#_ENREF_7)) and poorer patient outcomes([1](#_ENREF_1), [8](#_ENREF_8)) for patients with more comorbidities.

But how do we measure comorbidity? On existing data sources, i.e. in- and outpatient data and prescription data, diagnosed based (or prescription based) coding algorithms are often used to obtain a comorbidity measure([9](#_ENREF_9)) (i.e. Charlson Comorbidity Index (CCI), Elixhauser Score, and RxRisk-V). Inacio et al recently performed a study where the ability of Charlson Comorbidity Index (CCI), Elixhauser Score, and RxRisk-V to predict mortality after THA and TKA was evaluated in a research setting([10](#_ENREF_10)).

In our clinical departments an easily applicable tool with few dimensions is needed.

Today comorbidity measures such as the American Society of Anesthesiologists physical status classification (ASA) are preferred. ASA is easy to use but has not been validated as a predictor of 90-day mortality after THA and ASA is known to have a high degree of internal variability. ([11](#_ENREF_11)).Several universal and arthroplasty specific risk prediction tools of various complexity have been introduced but none has been broadly accepted.([12](#_ENREF_12" \o "Manning, 2016 #1318))

In this study we aimed to investigate how the clinically used comorbidity measure ASA influence the risk of early postoperative mortality compared to the diagnosed based CCI and Elixhauser Score and the prescription based RxRisk-V. We also aimed to investigate the prediction value of each comorbidity measure and of their included dimensions separately, in order to find a potentially usable comorbidity prediction tool for our clinical practise.

# Methods

## Study design and study population

We performed a nationwide retrospective cohort study (Figure 1). All patients operated between 2008 and 2013 for THA due to primary osteoarthritis from the Swedish Hip Arthroplasty Register (SHAR) were included. Only elective primary hip arthroplasty procedures were included in order to minimize the risk of selection bias.

Follow-up started on the date of surgery and ended on the day of death, emigration, or December 31st 2013, whichever came first. Only the first surgery was accounted for in bilaterally operated patients to avoid dependency issues. Potential reoperations within 90 days were not accounted for. Adjustment was made for age, gender, socioeconomic background, and type of hospital. Ninety days and one year mortality was the primary outcome measure.

## Sources of data

***The Swedish Hip Arthroplasty Register*** registers all patients undergoing THA in Sweden since 1979. The SHAR has a stable completeness of registration around 96-98% and has been validated repeatedly.([13-15](#_ENREF_13" \o "Soderman, 2000 #996))

***Statistics Sweden*** is a state-owned registry collecting information on the entire Swedish population i.e. level of education, personal and family income. Thanks to the ten-digit personal identity number all Swedish citizens are assigned at birth, linkage between different Swedish official and medical databases is made possible.

***The Swedish National Patient Register*** was started in 1964. It contains information on medical comorbidities and admissions to hospital care for all individuals in Sweden. The positive predictive value of the Swedish National Patient Register is estimated around 90±5% which indicates high validity of data.([16](#_ENREF_16" \o "Ludvigsson, 2011 #1090))

## Comorbidity measures

***The Charlson Comorbidity Index*** (CCI) is a diagnose based coding algorithm used in research.([17](#_ENREF_17)) It was developed to quantify the influence of comorbidities on survival. In this study the original weighting and the weighting according to Quan were investigated. ([17](#_ENREF_17" \o "Charlson, 1987 #1163), [18](#_ENREF_18" \o "Quan, 2011 #1091))

***The Elixhauser Score*** is also a diagnose based coding algorithm used in research. ([19](#_ENREF_19)) The Elixhauser Score is more detailed than the more commonly used CCI.

***The RxRisk-V Score*** is a pharmacy based coding algorithm used in research.([20](#_ENREF_20), [21](#_ENREF_21)) Prescription based comorbidity measures have been increasingly used over the last years. It has been argued that a prescription based measure would be more reliable than a diagnosed based measure, not having the same limitations such as incomplete or inaccurate coding.([22](#_ENREF_22" \o "Iezzoni, 1997 #1319), [23](#_ENREF_23" \o "Johnson, 2006 #1275))

***The American Society of Anesthesiologists physical status classification*** (ASA) is a six-category physical status evaluation system developed in 1941 and it has remained virtually unchanged([24](#_ENREF_24)). The ASA grade was included in the Swedish Hip Arthroplasty Register (SHAR) in 2008, which is why our study period begins that year. ASA is easily assessed in a clinical setting and has been compared to CCI previously but not in a THA population.([25](#_ENREF_25" \o "Kork, 2015 #1350), [26](#_ENREF_26" \o "Whitmore, 2014 #1349))

## Statistics

We adhered to the guidelines on statistical analyses of register data.([27](#_ENREF_27), [28](#_ENREF_28)) Means, medians and ranges were used to describe continuous data. 95% confidence intervals (CI) described estimation uncertainty. Categorical data were investigated by cross-tabulation and the Chi-square test. The Kaplan-Meier method was used to calculate unadjusted cumulative survival. In order to calculate crude and adjusted odds ratios (OR) with CI logistic regression models were fitted with adjustment for relevant factors i.e. age, gender, BMI, type of hospital, fixation method, comorbidity and socioeconomic position. Continuous variables were kept continuous when possible in order to strengthen the statistical analyses.([29](#_ENREF_29" \o "Altman, 2006 #1325))

The performance of the logistic regression models was evaluated by its discrimination capacity using c-statistics where the c-value stands for the degree of predictability. We performed no imputation for missing data.

## Ethical approval

All patients registered in the SHAR have received written information about the register. Registered patients have been given the choice not to participate in the registry or associated research but written informed consent for participation was not obtained. This is in consistency with the Swedish Patient Data Law from 2009. Our ethical approval was obtained from The Regional Ethical Review Board in Gothenburg (2013: 360-13).

# Results

Participants and comorbidities:

After the selection process (Figure 1) 44,214 individuals between 18 and 100 years old who hade undergone THA due to primary OA were analysed. The mean age was 68,3 years (SD 10.02) and there were somewhat more women (56.8%) than men (43.2%).

The highest proportion of patients with multiple comorbidities (i.e. three or more) was identified by the RxRisk-V measure (69.5%). For the Charlson Comorbidity Index the proportion of three or more comorbidities was 3.4% and for the Elixhauser Score it was 4.9%.

A vast majority of patients had an ASA score below three (85.2%). Individuals with an ASA score of 5 and 6 were excluded since those values describe moribund individuals.

See Table 1 for more characteristics of the study population.

## Ninety day mortality after THA

Unadjusted cumulative 90-day survival was 99.7 (CI 99.68 to 99.78) number of deaths 115. We found that age (OR 1,1 [CI 1.06-1.12]) and gender (female gender adjusted OR 0.4 [CI 0.28-0.64] were associated with on the adjusted risk of death. Crude values indicated an increased risk of 90-day mortality for all three comorbidity indexes. After adjustment was made only CCI and the clinical ASA score remained associated with an increased risk of 90-day mortality (adjusted OR 1.3[CI 1.09-1.45]). Within the social background variables only being a widow/-er (adjusted OR 1.7[CI 1.05-2.70]) fell out statistically significant after adjustment. Crude and adjusted odd ratios for 90-day mortality with 95% confidence intervals are presented in Table 2.

## Prediction strength of investigated comorbidity measures

***The Charlson Comorbidity Index*** When examining the CCIs different dimensions we found that the total CCI performed better in predicting 90-day and one-year mortality than the included dimensions separately. (See Table 3 A.) The original weighting (90-d c=0.65, 1-y c=0.65) was somewhat better in predicting both 90-day and one-year mortality than the weighting according to Quan (90-d c=0.61, 1-y c=0.63). The original weighting of Charlson performed best of all investigated comorbidity measures better in predicting 90-day mortality. (See Table 3 A-C.)

***The Elixhauser Score*** was better in predicting 90-day and one year mortality than the included dimensions separately (see Table 3B) with a 90 d AUC=0.63 and a 1 year AUC=0.65.

***The RxRisk-V Score*** performed better than diagnose based comorbidity measures (CCI and Elixhauser Score) in predicting 90-day mortality with an AUC= 0.66. (See Table 3 A-C.) The RxRisk-V Score performed better in predicting 90-day and one-year mortality than the included dimensions separately.

***The American Society of Anesthesiologists physical status classification***

ASA alone had a better prediction strength for both 90-day mortality (AUC=0.70) compared to the Elixhauser Score, CCI and RxRisk-V. The 1-year AUC was 0.66.

***Age, gender, ASA score, presence of heart infarction or renal disease combined the last 12 months*** After trying combinations of dimensions included in the different comorbidity measures and clinically accessible data we found that the combination of age, gender, ASA score, presence of heart infarction and renal disease the last 12 months gave the best prediction strength for 90-day and one year mortality)(AUC = 0.81). (See Table 4 and Figure 2 . Adding socioeconomic variables such as education level and civil status increased marginally the predictive power to 0.82, an insignificant increase (p =0.287).

# Discussion

## The impact of comorbidity on early postoperative mortality after THA

In this nation wide cohort study we wanted to investigate the performance of commonly used diagnosed based comorbidity coding algorithms (i.e. CCI and Elixhauser Score), an increasingly used prescription based comorbidity coding algorithm (i.e. RxRisk-V) with a clinically widely used comorbidity measures (i.e. ASA) with adjustment for other relevant factors such as age, gender and socioeconomic background. We found that the original CCI (AUC 0.65) performed somewhat better than the Elixhauser Score (AUC 0.63) in predicting 90-day mortality but in predicting one-year mortality the performed equally (AUC 0.65). The prescription based RxRisk-V Scoreperformed better than the diagnose based comorbidity scores (CCI and Elixhauser Score) in predicting 90-day mortality with an AUC of 0.66 but worse in predicting one year mortality (AUC 0.62). This differs from earlier findings by Inacio where the RxRisk-V did not perform as well as the CCI and Elixhauser Score and where the C- values generally were higher than in our study.([10](#_ENREF_10)) The study population of our study was younger and included more women and we only included diagnoses and prescriptions registered one year prior to surgery, which perhaps could at least partly explain the differences in the results.

Comorbidities are known to influence the outcome after THA.([1](#_ENREF_1), [7](#_ENREF_7" \o "Inacio, 2015 #1225), [8](#_ENREF_8)) In order to include the effect of comorbidity in research different comorbidity measures are used; either diagnosed based or prescription based. However, these comorbidity measures are not used in clinical settings and, not seldom they demand a merge of information from several data sources. Patient administrative data are easily accessible to researchers but are known to be incomplete. Coding errors and underreporting of certain conditions are common.([9](#_ENREF_9" \o "Bozic, 2013 #1347))

ASA is a comparatively old comorbidity measure that has stayed the same since its introduction([24](#_ENREF_24)). ASA has been repeatedly compared to CCI but no consensus as to which one is superior has been reached and, to our knowledge, it has not been done in a selected THA population.([25](#_ENREF_25), [26](#_ENREF_26)) In our study ASA had a better predictive capacity with an AUC of 0.70 for 90-day and 0.66 for 1 year mortality.

## The prediction strength

Risk prediction may be useful in the patient selection process, in the preoperative risk mitigation process of a patient and in research settings. A number of risk prediction tools for adverse outcomes after total joint replacements have been introduced on the market with various validation and performance measures. ([12](#_ENREF_12)) Using c-statistics we evaluated the prediction strength of different comorbidity measures intended for research and their included dimensions with that of a comorbidity measure intended for clinical use. Overall the predictive strength of the total index of the diagnose and prescription based measurements was better than the individual predictive strength of the included dimensions separately. ASA was better than the more complex coding algorithms. However, the best predictive strength was found for a model including age, gender, ASA score and presence of cardiac infarction or renal disease the last 12 months prior to THA surgery (AUC 0.81).

In regard to trauma outcome prediction tools are common and it is has been shown that a clinical evaluation tool with few variables included tend to have stronger prediction capacity than more complex ones.([30](#_ENREF_30)) Our results indicate that also for THA we should try to find risk prediction models not more detailed and complex but rather simpler and including the right variables. A risk prediction measurement of this kind would also have a smaller risk of coding errors etc.

## Strengths and limitations

Strength of this study is that it is nationwide with a large cohort with a reasonable number of events. The sources of data have been shown to a have a high validity of data and the risk of missing data or cohort attrition was low. ([13-16](#_ENREF_13)) Limitations are the potential bias at different levels associated with observational data and the risk of coding errors as expected when dealing with patient administrative data.

It is important to make a distinction between explanatory research and prediction research. In the latter, prediction research, the investigated temporal context is another i.e. *futurum*. In order for a risk factor to be considered a predictor, the investigated effect needs to be tested in a different sample of individuals to capture the “*futurum*” aspect. This has not been done. Hence it is only with extreme caution we can extrapolate our findings into predictions in the clinical setting. Our results indicate that, in research, a less data demanding comorbidity measure, i.e. the suggested combination of age, gender, ASA score, presence of heart infarction or renal disease for the last 12 months, serves us just as well if not better than the commonly used diagnose based or prescription based coding algorithms. It would be interesting to evaluate the effect on adverse events and revision rate within 2 years in the Swedish setting and validate the combination comorbidity measure on other populations in the future.

## Conclusion

Our results of this nationwide cohort study indicate that, in THA research, a less data demanding comorbidity measure, i.e. the suggested combination of age, gender, ASA score, presence of heart infarction or renal disease for the last 12 months prior to THA surgery or even ASA alone, serves us just as well if not better than the commonly used more complex diagnose based or prescription based coding algorithms in predicting early postoperative mortality.

## Contribution of authors

AG, NH: initiated the study and managed the ethical review board application. SN and AG performed the statistical analyses. GG: Assisted in preparing the review board application. AG drafted the manuscript. AG, SN, NH and GG took part in designing the study and editing the manuscript.

**Table 1:** Baseline demographic information on the study population 2008-2013.

|  |  |
| --- | --- |
|  |  |
| **No** | 44,214 |
|  |  |
| **Gender (%)** |  |
| Male | 19,114 (43.2) |
| Female | 25,100 (56.8) |
|  |  |

|  |  |
| --- | --- |
| **Age** (mean (sd[[1]](#footnote-1))) | 68.27 (10.02) |
|  |  |
| **BMI** (mean (sd)) | 27.27 (4.42) |
|  |  |
| **Level of education** (%) |  |
| Up to elementary | 15,362 (34.7) |
| High school | 17,995 (40.7) |
| University | 10,857 (24.6) |
|  |  |
| **Marital status** (%) |  |
| Couple | 25,095 (56.8) |
| Single | 12,366 (28.0) |
| Widow/-er | 6,753 (15.3) |
|  |  |
| **ASA** (%) |  |
| 1 | 11,405 (25.8) |
| 2 | 26,256 (59.4) |
| 3 | 6,553 (14.8) |
|  |  |
| **Elixhauser** (mean (sd)) | 0.79 (1.05) |
| 0 n(%) | 22,651 (51.2) |
| 1 | 12,081 (27.3) |
| 2 | 5,815 (13.2) |
| 3 | 2,146 ( 4.9) |
| NA | 997 ( 2.3) |
|  |  |
| **Charlson** (mean (sd)) | 0.40 (0.90) |
| 0 n(%) | 32963 (74.6) |
| 1 | 6514 (14.7) |
| 2 | 2827 ( 6.4) |
| 3 | 867 ( 2.0) |
| 4 | 519 ( 1.2) |
| NA | 524 ( 1.2) |
|  |  |
| **RxRiskV** (mean (sd)) | 4.08 (2.55) |
| 0 n(%) | 1,429 ( 3.2) |
| 1 | 5,689 (12.9) |
| 2 | 6,336 (14.3) |
| 3 | 6,123 (13.8) |
| 4 | 5,870 (13.3) |
| 5 | 5,118 (11.6) |
| 6 | 4,264 ( 9.6) |
| 7 | 7,480 (16.9) |
| NA | 1,905 ( 4.3) |
|  |  |
| **Type of hospital** (%) |  |
| University | 3,088 ( 7.0) |
| County | 14,115 (31.9) |
| Rural | 18,211 (41.2) |
| Private | 8,800 (19.9) |
|  |  |
| **Fixation method** (%) |  |
| Cemented | 30,509 (69.0) |
| Uncemented | 6,997 (15.8) |
| Hybrid | 613 ( 1.4) |
| Reversed\_hybrid | 6,095 (13.8) |
|  |  |

**Table 2.** Crude and adjusted odd ratios for 90-day mortality with 95% confidence intervals. AUC values for the included variables.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Crude** | | | **Adjusted** | |
|  | **OR** | **CI (95%)** | **AUC** | **OR** | **CI (95%)** |
|  |  |  |  |  |  |
| **Age** | 1.1 | 1.09-1.14 | 0.74 | 1.1 | 1.06-1.12 |
|  |  |  |  |  |  |
| **Gender[[2]](#footnote-2)** |  |  | 0.58 |  |  |
| Female | 0.5 | 0.36-0.76 |  | 0,4 | 0.28-0.64 |
|  |  |  |  |  |  |
| **BMI** | 1.0 | 0.93-0.01 | 0.55 | 1.0 | 0.95-1.04 |
|  |  |  |  |  |  |
| **Type of hospital[[3]](#footnote-3)** |  |  | 0.55 |  |  |
| County | 0.9 | 0.44-1.66 |  | 0.9 | 0.44-1.70 |
| Rural | 0.7 | 0.36-1.34 |  | 0.8 | 0.40-1.57 |
| Private | 0.5 | 0.24-1.10 |  | 0.8 | 0.38-1.89 |
|  |  |  |  |  |  |
| **Fixation method[[4]](#footnote-4)** |  |  | 0.60 |  |  |
| Uncemented | 0.1 | 0.04-0.41 |  | 0.4 | 0.13-1.40 |
| Hybrid | 0.5 | 0.07-3.57 |  | 0.6 | 0.08-4.20 |
| Reversed hybrid | 0.6 | 0.29-1.03 |  | 1.1 | 0.59-2.15 |
|  |  |  |  |  |  |
| **ASA[[5]](#footnote-5)** |  |  | 0.70 |  |  |
| 2 | 5.1 | 2.06-12.80 |  | 2.8 | 1.08-7.10 |
| 3 | 17.9 | 7.13-44.83 |  | 5.4 | 1.96-14.77 |
|  |  |  |  |  |  |
| **Elixhauser index** | 1.5 | 1.37-1.73 | 0.63 | 1.0 | 0.82-1.20 |
|  |  |  |  |  |  |
| **Charlson index[[6]](#footnote-6)** | 1.5 | 1.35-1.60 | 0.65 | 1.3 | 1.09-1.45 |
|  |  |  |  |  |  |
| **RxRiskV index** | 1.2 | 1.12-1.27 | 0.65 | 1.0 | 0.94-1.10 |
|  |  |  |  |  |  |
| **Level of education[[7]](#footnote-7)** |  |  | 0.56 |  |  |
| High school | 0.6 | 0.40-0.93 |  | 1.0 | 0.63-1.48 |
| University | 0.7 | 0.44-1.13 |  | 1.3 | 0.82-2.16 |
|  |  |  |  |  |  |
| **Marital status[[8]](#footnote-8)** |  |  | 0.58 |  |  |
| Single | 1.1 | 0.66-1.68 |  | 1.4 | 0.89-2.30 |
| Widow/-er | 2.6 | 1.69-3.95 |  | 1.7 | 1.05-2.70 |

**Table 3 A-C:** Odd ratios with 95% CI and AUC values for the three investigated coding algoritms and their included dimensions. A Elixhauser Score, B Charlson Comorbidity Index and C RxRisk-V.

**A:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | |
| **Elixhauser** | **OR** | **90 d**  **CI(95%)** | **AUC** | **OR** | **1 year**  **CI(95%)** | **AUC** |
|  |  |  |  |  |  |  |
| Congestive heart failure | 9.3 | 5.63- 14.68 | 0.58 | 5.7 | 4.06- 7.78 | 0.55 |
| Cardiac arrhythmias | 2.8 | 1.70- 4.50 | 0.55 | 2.37 | 1.75- 3.14 | 0.54 |
| Valvular disease | 1.3 | 0.32- 3.42 | 0.50 | 1.8 | 0.98- 3.01 | 0.51 |
| Pulmonary circulation disorder | 7.0 | 1.71- 18.81 | 0.51 | 4.45 | 1.74- 9.27 | 0.51 |
| Peripheral vascular disorder | 3.5 | 1.08- 8.45 | 0.51 | 2.5 | 1.19- 4.60 | 0.51 |
| Hypertension uncomplicated | 1.3 | 0.88-1.88 | 0.53 | 1.35 | 1.09- 1.66 | 0.53 |
| Hypertension complicated | 4.5 | 1.10- 12.02 | 0.51 | 2.8 | 1.12- 5.87 | 0.51 |
| Paralysis | 0 | 0- 4.87 | 0.50 | 2.5 | 0.42-8.00 | 0.50 |
| Other neurological disorders | 3.2 | 0.97- 7.59 | 0.51 | 2.0 | 0.90-3.77 | 0.51 |
| Chronic pulmonary disease | 1.6 | 0.77- 3.06 | 0.51 | 1.68 | 1.12- 2.42 | 0.52 |
| Diabetes uncomplicated | 1.5 | 0.78- 2.63 | 0.52 | 1.65 | 1.17-2.26 | 0.52 |
| Diabetes complicated | 2.3 | 0.55- 5.93 | 0.51 | 2.38 | 1.18-4.25 | 0.51 |
| Hypothyroidism | 1.3 | 0.47-2.92 | 0.51 | 1.25 | 0.71- 2.03 | 0.50 |
| Renal failure | 11.6 | 5.65- 21.34 | 0.54 | 6.1 | 3.56-9.71 | 0.52 |
| Liver disease | 0 | 0-6.59 | 0.50 | 2.7 | 0.95- 5.90 | 0.50 |
| Peptic ulcer disease | 2.7 | 0.15- 12.30 | 0.50 | 3.5 | 1.08- 8.38 | 0.50 |
| Aids/hiv | 0 | NA-54218648.46 | 0.50 | 17.1 | 0.91- 96.41 | 0.50 |
| Lymphoma | 5.3 | 0.86- 16.67 | 0.51 | 5.1 | 1.98- 10.59 | 0.51 |
| Metastatic cancer | 3.0 | 0.17- 13.37 | 0.50 | 9.1 | 4.25- 17.02 | 0.51 |
| Solid\_tumor | 2.3 | 1.11- 4.14 | 0.52 | 4.3 | 3.15- 5.67 | 0.56 |
| Rheumatoid arthritis | 1.7 | 0.66- 3.51 | 0.51 | 1.5 | 0.89- 2.37 | 0.51 |
| Coagulopathy | 2.4 | 0.14- 11.02 | 0.50 | 1.5 | 0.26- 4.85 | 0.50 |
| Obesity | 1.6 | 0.57-3.57 | 0.51 | 0.7 | 0.30- 1.36 | 0.50 |
| Weight loss | 0 | 0- 358.25 | 0.50 | 0 | 0- 0.69 | 0.50 |
| Fluid electrolyte disorders | 0 | 0- 0.14 | 0.50 | 2.6 | 0.79- 6.13 | 0.50 |
| Blood loss anemia | 14.1 | 0.79-67.28 | 0.50 | 4.4 | 0.25- 20.87 | 0.50 |
| Deficiency anemia | 2.6 | 0.44- 8.36 | 0.51 | 4.3 | 2.13- 7.77 | 0.51 |
| Alcohol\_abuse | 2.1 | 0.12- 9.27 | 0.50 | 2.0 | 0.48- 5.19 | 0.50 |
| Drug abuse | 0 | 0- 58.13 | 0.50 | 0 | 0- 0.11 | 0.50 |
| Psychoses | 4.2 | 0.24- 19.07 | 0.50 | 4.05 | 0.99- 10.85 | 0.50 |
| Depression | 0.6 | 0.03- 2.50 | 0.50 | 1.6 | 0.77- 2.98 | 0.51 |
| Elixhauser index | 1.5 | 1.36- 1.72 | 0.63 | 1.5 | 1.41- 1.62 | 0.65 |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

**B:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Charlson** | **OR** | **90 d**  **CI(95%)** | **AUC** | **OR** | **1 year**  **CI(95%)** | **AUC** |
|  |  |  |  |  |  |  |
| Myocardial infarction | 4.4 | 2.51- 7.11 | 0.56 | 3.0 | 2.18- 4.26 | 0.54 |
| Congestive heart failure | 9.8 | 5.91- 15.42 | 0.58 | 6.0 | 4.32- 8.28 | 0.55 |
| Peripheral vascular disease | 3.5 | 1.08- 8.45 | 0.51 | 2.5 | 1.29- 4.89 | 0.51 |
| Cerebrovascular disease | 3.9 | 1.76- 7.61 | 0.53 | 2.9 | 1.84- 4.68 | 0.52 |
| Dementia | 4.9 | 0.80- 15.49 | 0.51 | 3.1 | 1.14- 8.36 | 0.50 |
| Chronic pulmonary disease | 1.6 | 0.77- 3.06 | 0.51 | 1.7 | 1.15- 2.46 | 0.52 |
| Rheumatic disease | 2.1 | 0.81- 4.35 | 0.51 | 1.6 | 0.97- 2.75 | 0.51 |
| Peptic ulcer disease | 1.4 | 0.08- 6.49 | 0.50 | 2.3 | 0.95- 5.66 | 0.50 |
| Mild liver disease | 0 | 0- 9.47 | 0.50 | 2.8 | 1.16- 6.90 | 0.50 |
| Diabetes no complication | 1.5 | 0.77- 2.57 | 0.52 | 1.7 | 1.24- 2.35 | 0.52 |
| Charlson diabetes complication | 2.0 | 0.33- 6.41 | 0.50 | 1.3 | 0.47- 3.44 | 0.50 |
| Hemiplegia or paraplegia | 0 | 0- 4.87 | 0.50 | 2.5 | 0.62- 10.27 | 0.50 |
| Renal disease | 11.3 | 5.48- 20.68 | 0.54 | 5.9 | 3.58- 9.70 | 0.52 |
| Malingnacy | 2.7 | 1.45-4.67 | 0.53 | 4.6 | 3.47- 6.02 | 0.57 |
| Moderate or severe liver disease | 0 | NA- 634.03 | 0.50 | 0 | 0- 1.343E+149 | 0.50 |
| Metastasic solid tumor | 3.0 | 0.17- 13.37 | 0.50 | 9.1 | 4.58-18.01 | 0.51 |
| Aids/hiv | 0 | NA- 54218648.50 | 0.50 | 17.1 | 2.10-139.30 | 0.50 |
| Charlson index\_original | 1.5 | 1.34- 1.59 | 0.65 | 1.5 | 1.42- 1.58 | 0.65 |
| Charlson index updated | 1.5 | 1.33- 1.60 | 0.61 | 1.5 | 1.44-1.60 | 0.63 |
|  |  |  |  |  |  |  |

**C:**


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **RcRiskV** | **OR** | **90 d**  **CI(95%)** | **AUC** | **OR** | **1 year**  **CI(95%)** | **AUC** |
|  |  |  |  |  |  |  |
| Alcohol dependence | 2.6 | 0.15- 11.86 | 0.50 | 1.7 | 0.41-6.73 | 0.50 |
| Allergies | 0.7 | 0.30- 1.27 | 0.52 | 0.8 | 0.52- 1.12 | 0.51 |
| Anti coagulation therapy | 1.8 | 0.96- 2.98 | 0.53 | 1.8 | 1.32- 2.47 | 0.53 |
| Anti platelet therapy | 2.1 | 1.44- 3.11 | 0.58 | 1.8 | 1.41- 2.20 | 0.56 |
| Anxiety | 2.2 | 1.24- 3.71 | 0.54 | 1.9 | 1.41- 2.70 | 0.53 |
| Arrhythmia | 2.5 | 0.89- 5.62 | 0.51 | 2.3 | 1.31- 3.86 | 0.51 |
| Benign prostate hypertrophy | 1.8 | 0.62-3.90 | 0.51 | 2.0 | 1.26- 3.29 | 0.51 |
| Bipolar disorder | 0.4 | 0.02- 1.87 | 0.51 | 1.5 | 0.82- 2.74 | 0.51 |
| Chronic heart failure | 2.3 | 1.61-3.49 | 0.61 | 1.8 | 1.46- 2.24 | 0.57 |
| Dementia | NA | NA- NA | 0.50 | NA | NA-NA | 0.50 |
| Depression | 0.7 | 0.35- 1.29 | 0.52 | 1.1 | 0.84- 1.54 | 0.51 |
| Diabetes | 2.2 | 1.29- 3.58 | 0.54 | 1.8 | 1.31- 2.42 | 0.53 |
| End stage renal disease | 7.8 | 2.36- 18.73 | 0.52 | 9.8 | 5.72- 16.72 | 0.52 |
| Epilepsy | 1.7 | 0.52- 4.07 | 0.51 | 2.1 | 1.22- 3.46 | 0.51 |
| Gastric oesophageal reflux disorder | 0.8 | 0.47- 1.21 | 0.52 | 1.3 | 0.99- 1.58 | 0.52 |
| Glaucoma | 1.4 | 0.59-2.82 | 0.51 | 1.1 | 0.71- 1.83 | 0.50 |
| Gout | 2.3 | 0.90-4.83 | 0.52 | 2.5 | 1.56- 3.89 | 0.52 |
| Hepatitis C | 1.4 | 0.24- 4.55 | 0.50 | 1.1 | 0.47- 2.76 | 0.50 |
| Hiv | 0 | NA-26514.03 | 0.50 | 14.3 | 3.29- 62.14 | 0.50 |
| Hyperkalaemia | 0 | 0- 21257.96 | 0.50 | 0 | 0-2.0E+214 | 0.50 |
| Hyperlipidemia | 1.5 | 0.98- 2.17 | 0.54 | 1.5 | 1.17- 1.82 | 0.54 |
| Hypertension | 2.3 | 1.61-3.44 | 0.60 | 1.5 | 1.25- 1.91 | 0.55 |
| Hyperthyroidism | 1.0 | 0.50- 1.87 | 0.50 | 0.9 | 0.61- 1.32 | 0.50 |
| Angina | 4.4 | 2.71- 6.86 | 0.58 | 2.9 | 2.14- 3.90 | 0.55 |
| Ischaemic heart disease hypertension | 3.7 | 2.47- 5.65 | 0.66 | 2.0 | 1.63- 2.50 | 0.59 |
| Inflammatory bowel disease | 4.1 | 1.25- 9.83 | 0.51 | 2.2 | 1.05- 4.77 | 0.51 |
| Liver failure | 3.4 | 1.81- 5.84 | 0.54 | 3.0 | 2.09- 4.19 | 0.53 |
| Malignancies | 2.1 | 0.12- 9.45 | 0.50 | 5.6 | 2.72- 11.40 | 0.51 |
| Malnutrition | 0 | NA- 3.20E+22 | 0.50 | 0 | 0- 1.2E+192 | 0.50 |
| Migraine | 0 | 0-0.25 | 0.51 | 0.3 | 0.04- 2.19 | 0.50 |
| Osteoporosis pagets | 2.0 | 0.94- 3.76 | 0.52 | 1.7 | 1.11- 2.55 | 0.51 |
| Pain | 1.3 | 0.88- 1.87 | 0.53 | 1.3 | 1.05- 1.61 | 0.53 |
| Inflammation pain | 0.4 | 0.26- 0.57 | 0.62 | 0.4 | 0.31- 0.48 | 0.62 |
| Pancreatic insufficiency | 0 | 0- 2.28 | 0.50 | 2.1 | 0.52- 8.50 | 0.50 |
| Parkinsons disease | 1.3 | 0.32- 3.48 | 0.50 | 1.7 | 0.94- 3.00 | 0.51 |
| Psoriasis | 2.2 | 0.36-6.89 | 0.51 | 0.7 | 0.17- 2.73 | 0.50 |
| Psychotic illness | 2.5 | 0.61- 6.63 | 0.51 | 1.8 | 0.86- 3.90 | 0.51 |
| Chronic airways disease | 1.3 | 0.73- 2.25 | 0.51 | 1.1 | 0.80- 1.57 | 0.51 |
| Smoking cessation | 0 | 0- 0.61 | 0.50 | 0.4 | 0.05- 2.55 | 0.50 |
| Steroid responsive diseases | 1.7 | 0.99- 2.80 | 0.53 | 1.5 | 1.14- 2.10 | 0.52 |
| Transplant | 0 | 0- 253.43 | 0.50 | 0 | 0- 1.9E+237 | 0.50 |
| Tuberculosis | 0 | NA-212367.77 | 0.50 | 0 | 0- 9.9E+177 | 0.50 |
| RcRiskV index | 1.2 | 1.14-1.29 | 0.66 | 1.2 | 1.12-1.21 | 0.62 |



**Figure 1.** Flowchart.



**Figure 2:** ROC-curve of the model with age, gender, ASA, presence of heart infarction or renal disease during the last 12 months in regard to 90-day and 1 year mortality.



# Bibliography

1. Gordon M, Stark A, Skoldenberg OG, Karrholm J, Garellick G. The influence of comorbidity scores on re-operations following primary total hip replacement: comparison and validation of three comorbidity measures. Bone Joint J. 2013;95-B(9):1184-91.

2. Singh JA, Lewallen DG. Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends. BMC musculoskeletal disorders. 2014;15:441.

3. Aynardi M, Pulido L, Parvizi J, Sharkey PF, Rothman RH. Early mortality after modern total hip arthroplasty. Clinical orthopaedics and related research. 2009;467(1):213-8.

4. McMinn DJ, Snell KI, Daniel J, Treacy RB, Pynsent PB, Riley RD. Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study. Bmj. 2012;344:e3319.

5. Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, et al. 90-day mortality after 409,096 total hip replacements for osteoarthritis, from the National Joint Registry for England and Wales: a retrospective analysis. Lancet. 2013;382(9898):1097-104.

6. Lalmohamed A, Vestergaard P, de Boer A, Leufkens HG, van Staa TP, de Vries F. Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study. Arthritis Rheumatol. 2014;66(2):311-8.

7. Inacio MC, Pratt NL, Roughead EE, Graves SE. Using Medications for Prediction of Revision after Total Joint Arthroplasty. The Journal of arthroplasty. 2015;30(12):2061-70.

8. Hofstede SN, Gademan MG, Vliet Vlieland TP, Nelissen RG, Marang-van de Mheen PJ. Preoperative predictors for outcomes after total hip replacement in patients with osteoarthritis: a systematic review. BMC musculoskeletal disorders. 2016;17:212.

9. Bozic KJ, Bashyal RK, Anthony SG, Chiu V, Shulman B, Rubash HE. Is administratively coded comorbidity and complication data in total joint arthroplasty valid? Clinical orthopaedics and related research. 2013;471(1):201-5.

10. Inacio MC, Pratt NL, Roughead EE, Graves SE. Evaluation of three co-morbidity measures to predict mortality in patients undergoing total joint arthroplasty. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. 2016;24(10):1718-26.

11. Haynes SR, Lawler PG. An assessment of the consistency of ASA physical status classification allocation. Anaesthesia. 1995;50(3):195-9.

12. Manning DW, Edelstein AI, Alvi HM. Risk Prediction Tools for Hip and Knee Arthroplasty. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(1):19-27.

13. Soderman P, Malchau H, Herberts P, Johnell O. Are the findings in the Swedish National Total Hip Arthroplasty Register valid? A comparison between the Swedish National Total Hip Arthroplasty Register, the National Discharge Register, and the National Death Register. The Journal of arthroplasty. 2000;15(7):884-9.

14. Swedish Hip Arthroplasty Register (SHAR). The Annual Report 2014. <http://www.shpr.se/>.

15. Soderman P, Malchau H, Herberts P, Zugner R, Regner H, Garellick G. Outcome after total hip arthroplasty: Part II. Disease-specific follow-up and the Swedish National Total Hip Arthroplasty Register. Acta Orthop Scand. 2001;72(2):113-9.

16. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.

17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.

18. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-82.

19. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Medical care. 1998;36(1):8-27.

20. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Medical care. 2003;41(1):84-99.

21. Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Medical care. 2003;41(6):761-74.

22. Iezzoni LI. Assessing quality using administrative data. Annals of internal medicine. 1997;127(8 Pt 2):666-74.

23. Johnson ML, El-Serag HB, Tran TT, Hartman C, Richardson P, Abraham NS. Adapting the Rx-Risk-V for mortality prediction in outpatient populations. Medical care. 2006;44(8):793-7.

24. Saklad M. Grading of patients for surgical procedures. Anesthesiology. 1941;2:281-4.

25. Kork F, Balzer F, Krannich A, Weiss B, Wernecke KD, Spies C. Association of comorbidities with postoperative in-hospital mortality: a retrospective cohort study. Medicine. 2015;94(8):e576.

26. Whitmore RG, Stephen JH, Vernick C, Campbell PG, Yadla S, Ghobrial GM, et al. ASA grade and Charlson Comorbidity Index of spinal surgery patients: correlation with complications and societal costs. The spine journal : official journal of the North American Spine Society. 2014;14(1):31-8.

27. Ranstam J, Karrholm J, Pulkkinen P, Makela K, Espehaug B, Pedersen AB, et al. Statistical analysis of arthroplasty data. I. Introduction and background. Acta orthopaedica. 2011;82(3):253-7.

28. Ranstam J, Karrholm J, Pulkkinen P, Makela K, Espehaug B, Pedersen AB, et al. Statistical analysis of arthroplasty data. II. Guidelines. Acta orthopaedica. 2011;82(3):258-67.

29. Altman DG, Royston P. The cost of dichotomising continuous variables. Bmj. 2006;332(7549):1080.

30. Gerdin M, Roy N, Khajanchi M, Kumar V, Fellander-Tsai L, Petzold M, et al. Validation of a novel prediction model for early mortality in adult trauma patients in three public university hospitals in urban India. BMC emergency medicine. 2016;16:15.

1. sd=Standard Deviation [↑](#footnote-ref-1)
2. Ref. = Male [↑](#footnote-ref-2)
3. Ref.= University hospital [↑](#footnote-ref-3)
4. Ref. = Uncemented [↑](#footnote-ref-4)
5. Ref. = 1 [↑](#footnote-ref-5)
6. Ref.= Original weigting [↑](#footnote-ref-6)
7. Ref.= Up to elementary [↑](#footnote-ref-7)
8. Ref.= Couple [↑](#footnote-ref-8)